Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-01-04
2011-01-04
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C548S146000
Reexamination Certificate
active
07863263
ABSTRACT:
An EP2 agonist which may have an EP3 agonistic effect has an effect of regenerating and/or protecting nerves, and is therefore useful as a therapeutic agent for a disease of the peripheral nervous system, such as a lower or upper motor neuron disease, a nerve root disease, plexopathy, thoracic outlet compression syndrome, peripheral neuropathy, neurofibromatosis and neuromuscular transmission disease. An EP2 agonist which has an EP3 agonistic effect is a safe and effective agent for the regeneration and/or protection of nerves which has little influence on the circulatory system.
REFERENCES:
patent: 6288119 (2001-09-01), Ohuchida
patent: 2005/0020686 (2005-01-01), Maruyama et al.
patent: 2005/0124577 (2005-06-01), Tani et al.
patent: 2006/0109102 (2006-05-01), Gortz et al.
patent: 2007/0129327 (2007-06-01), Ohmoto
patent: 2008/0021021 (2008-01-01), Okada et al.
patent: 0 156 611 (1985-10-01), None
patent: 1 481 976 (2004-12-01), None
patent: 1586564 (2005-10-01), None
patent: 1609480 (2005-12-01), None
patent: 1 806 148 (2007-07-01), None
patent: 11-130678 (1999-05-01), None
patent: 03/009872 (2003-02-01), None
patent: WO 03/009872 (2003-02-01), None
patent: 03/074483 (2003-09-01), None
patent: WO 03/074483 (2003-09-01), None
patent: 2004/065365 (2004-08-01), None
patent: WO 2004/065365 (2004-08-01), None
patent: 2004/089411 (2004-10-01), None
patent: WO 2004/089411 (2004-10-01), None
patent: 2005053707 (2005-06-01), None
patent: 2005061492 (2005-07-01), None
patent: 2006016689 (2006-02-01), None
patent: 2006043655 (2006-04-01), None
Y. Liu, “Rat Umao Shinkei Appaku Hoko Shogai Model Deno Beraprost Natrium to Limaprostal fadex Tono Hikaku”, Basic Pharmacology & Therapeutics, 2002 pp. 875-880, vol. 30, No. 10.
M. Kiriyama, “Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells”, 1997, pp. 217-224, vol. 122, No. 2.
H. Kuwada, “Effects of prostaglandin derivatives on changes of gastric mucosal protein contents in ethanol-induced ulcer”, Cyto-protection & Biology, 1985, pp. 217-225, vol. 3.
Kiyohiro Tsutsui, “Procylin Naifuku Toya go Soki Shita Livedo Kekkan'en no 1 Rei”, The Journal of Medicine, 1994, pp. 611-613, vol. 32, No. 3.
International Search Report (PCT/ISA/210) for PCT/JP04/017961, dated Feb. 1, 2005.
Bilak, M. et al., PGE2 Receptors Rescue Motor Neurons in a Model of Amyotrophic Lateral Sclerosis, Annals of Neurology, 2004, vol. 56, No. 2, pp. 240 to 248, full test, particularly, p. 243, left column, line 48 to p. 244, line 11, Fig 3., abstract, lines 1 to 3.
Supplementary European Search Report dated Feb. 12, 2010 in European Application No. 04819909.5.
Kato et al., “Successful Treatment of Intermittent Claudication Due to Spinal Canal Stenosis Using Beraprost Sodium, a Stable Prostaglandin I2 Analogue,” The Journal of Vascular Diseases, vol. 48, No. 5, pp. 457-461 (1997).
Yone et al., “The effect of Lipo prostaglandin E1 on cauda equina blood flow in patients with lumbar spinal canal stenosis: myeloscopic observation,” Spinal Cord, vol. 37, No. 4, pp. 269-274 (1999).
Konno et al., “Effects of OP-1206 (Prostaglandin E1) on Nerve-Conduction Velocity in the Dog Cauda Equina Subjected to Acute Experimental Compression,” Journal of Spinal Disorders, vol. 9, No. 2, pp. 103-106 (1996).
Orendacova et al., “Cauda equina syndrome,” Progress in Neurobiology, vol. 64, No. 6, pp. 613-637 (2001).
Extended European Search Report dated Feb. 2, 2010 in European Application No. 06756919.4.
Israeli Office Action issued in Counterpart Application No. 187840; dated Mar. 10, 2010.
New Zealand Office Action, in corresponding New Zealand Application No. 563863, issued Jul. 1, 2010.
European Office Action, in corresponding European Application No. 06756919.4, issued Jun. 10, 2010.
Russian Office Action, in corresponding Russian Application No. 2007148992, issued Jun. 23, 2010.
Chinese Office Action, in Chinese Application No. 2006800286854, issued Jun. 9, 2010.
Kinoshita Akihiro
Matsuya Hidekazu
Ohmoto Kazuyuki
Fetterolf Brandon J
Ono Pharmaceutical Co. Ltd.
Stone Christopher R
Sughrue & Mion, PLLC
LandOfFree
Agent for regeneration and/or protection of nerves does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agent for regeneration and/or protection of nerves, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for regeneration and/or protection of nerves will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2708446